GNAI3 demonstrated statistical significance in primary and recurrent gliomas; consequently, we conducted an in-depth analysis to assess its role as a potential prognostic biomarker for GBM because it demonstrated a high mRNA expression that was highly significant. This evidence concerns the gene GNAI3 and central nervous system cancer.